Exosome Diagnostics Appoints Mario Morken as Director of Business Development
Cambridge, MA- June 27, 2016 - Exosome Diagnostics, Inc., the world’s only provider of a revolutionary liquid biopsy platform that enables analysis of both living and dying processes of disease states in one reaction, thus aiming to reduce or eliminate the need for tissue biopsies, today announced the appointment of Mario Morken as Director of Business Development.
“I am honored to join Exosome Diagnostics and lead the expansion of the company’s companion diagnostics business unit,” stated Mario Morken, Director of Business Development. “Working in conjunction with the dynamic team assembled at Exosome Diagnostics, the companion diagnostics business unit will leverage the company’s proprietary cell free DNA + exosomal RNA technology, as well as ancillary technologies, with pharmaceutical companies to help speed biomarker discovery, subject selection, and companion diagnostics development via liquid biopsies at a faster rate than currently realized in the industry,” Morken continued.
Mario Morken brings over 10 years of experience in molecular biology, genomics, product management, and marketing. Mario began his career at the bench working as a research associate for a private biotech company before moving to the National Institutes of Health (NIH). At NIH, he spent over six years as a researcher in the laboratory of NIH Director Francis Collins MD. PhD. Mario’s research focused on the genetics and epigenetics of type 2 diabetes and is a co-author on over 25 peer reviewed publications. Prior to joining Exosome Diagnostics, Mario served as a Senior Product Manager at Bio-Rad Laboratories where he was responsible for their next generation sequencing product. Prior to that, Mario was a product manager at Thermo Fisher Scientific where he managed their next generation sequencing benchtop platform. Mario has a bachelor’s degree in Biology from Loyola University Maryland. He earned his Masters of Business Administration and Master’s in Biotechnology degrees from the Johns Hopkins University.
“As we grow the company’s companion diagnostics business by selectively working with cutting edge pharmaceutical companies utilizing Exosome’s proprietary liquid biopsy platform, we have formed and staffed essential departments that will help garner results faster for those partner companies,” stated John Boyce, President and CEO of Exosome Diagnostics. “This includes an experienced Regulatory department, as well as an Informatics and Software department that is working in conjunction with Regulatory to develop novel tools that our partners can access,” Boyce continued. “A key component of this pipeline is the business development arm. I am thrilled to have Mario leading the Business Development and Companion Diagnostics business division at Exosome Diagnostics. Mario brings an unsurpassed work ethic and knowledge of the pharmaceutical industry that will contribute significantly to the growth of Exosome Diagnostic’s world-class companion diagnostics division.”
About Exosome Diagnostics
Exosome Diagnostics is a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The company’s novel exosome-based technology platform, ExoLutionTM, can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. Visit www.exosomedx.com to learn more.
ExoDx is a registered trademark of Exosome Diagnostics, Inc. Exosome Diagnostics and ExoLution are unregistered trademarks of Exosome Diagnostics, Inc.
Feinstein Kean Healthcare